[SCHEDULE 13G] Vivos Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G filing for Vivos Therapeutics, Inc. (VVOS) discloses that individual investor Dawei Luo beneficially owns 572,016 common shares, representing 8.52 % of the outstanding class. The stake consists of 445,205 shares held directly and 126,811 shares held through wholly-owned Space Star Holding Ltd. Luo retains sole voting and dispositive power over the entire position and reports no shared power. The filing is made on a passive basis under Rule 13d-1(c); the investor certifies the shares were not acquired to influence control of the issuer. Ownership percentages are calculated against 6,717,520 shares outstanding (per the company’s May 15 2025 10-Q plus shares issued June 9 2025). No other members, subsidiaries, or group arrangements are reported, and there are no indications of additional transactions or intentions. The disclosure mainly informs the market of a new >5 % holder, which may affect float and governance considerations but contains no financial performance data.

Positive

• Material stake disclosed: a single investor now controls 8.52 % of VVOS, highlighting external confidence and potentially improving shareholder support.

Negative

• None.

Insights

Equity Ownership Analyst

TL;DR – Passive 8.5 % stake; neutral governance impact.

This Schedule 13G reveals Dawei Luo as a new significant shareholder in VVOS with 8.52 % of common stock. Because the filing is on Form 13G (not 13D), Luo claims a passive investment intent, limiting immediate governance implications. The size is material relative to VVOS’s small float, potentially tightening liquidity and signaling outside confidence. However, there is no purchase price, lock-up, or strategic plan disclosed. Overall, the filing is informative but not inherently catalytic; valuation impact will depend on market perception of Luo’s motives and future actions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Vivos Therapeutics Inc.

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

92859E207

(CUSIP Number)

07/08/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 92859E207

1

Names of Reporting Persons

Dawei Luo

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 572,016.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 572,016.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

572,016.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.52 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The percentage is calculated based upon (i) 5,889,520 shares of Common Stock issued and outstanding as of May 15, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the SEC on May 15, 2025, plus (ii) 828,000 shares of Common Stock issued to V-Co Investors 2 LLC on June 9, 2025 in connection with a private financing between V-Co Investors 2 LLC and the Company.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Vivos Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 7921 Southpark Plaza, Suite 210 Littleton, CO, 80120
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of Dawei Luo, an individual (the "Reporting Person").
(b)	Address or principal business office or, if none, residence: The principal business office of Dawei Luo is 2/F, Palm Grove House, P.O. Box 3340, Road Town, Tortola, British Virgin Island.
(c)	Citizenship: Dawei Luo is a citizen of the People's Republic of China.
(d)	Title of class of securities: Common stock, par value $0.0001 per share
(e)	CUSIP No.: 92859E207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) 445,205 shares of common stock directly owned by the Reporting Person, and (ii) 126,811 shares of common stock directly owned by Space Star Holding Ltd, a British Virgin Islands company wholly owned by the Reporting Person.
(b)	Percent of class: 8.52%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 572,016
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 572,016
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dawei Luo

Signature:	/s/ Dawei Luo
Name/Title:	Dawei Luo
Date:	07/14/2025

FAQ

How many VVOS shares does Dawei Luo own?

The filing reports 572,016 common shares beneficially owned.

What percentage of Vivos Therapeutics does the 572,016-share stake represent?

It represents 8.52 % of the outstanding common stock.

Is the ownership held directly or through entities?

445,205 shares are held directly by Dawei Luo and 126,811 shares through Space Star Holding Ltd, his wholly owned BVI company.

Does the investor have shared voting power in VVOS?

No. The filing states sole voting and dispositive power over all reported shares.

Is this a passive or activist position?

The Form 13G was filed under Rule 13d-1(c), indicating a passive investment intent without plans to influence control.